- Home
- ONL vs IMUX Comparison
ONL vs IMUX Comparison
Compare ONL & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONL
- IMUX
- Stock Information
- Founded
- ONL 2021
- IMUX 2016
- Country
- ONL United States
- IMUX United States
- Employees
- ONL N/A
- IMUX N/A
- Industry
- ONL Real Estate Investment Trusts
- IMUX Biotechnology: Pharmaceutical Preparations
- Sector
- ONL Real Estate
- IMUX Health Care
- Exchange
- ONL Nasdaq
- IMUX Nasdaq
- Market Cap
- ONL 111.3M
- IMUX 107.3M
- IPO Year
- ONL N/A
- IMUX N/A
- Fundamental
- Price
- ONL $1.93
- IMUX $0.70
- Analyst Decision
- ONL Hold
- IMUX Strong Buy
- Analyst Count
- ONL 1
- IMUX 6
- Target Price
- ONL N/A
- IMUX $11.60
- AVG Volume (30 Days)
- ONL 636.5K
- IMUX 1.4M
- Earning Date
- ONL 05-07-2025
- IMUX 05-15-2025
- Dividend Yield
- ONL 4.12%
- IMUX N/A
- EPS Growth
- ONL N/A
- IMUX N/A
- EPS
- ONL N/A
- IMUX N/A
- Revenue
- ONL $154,796,000.00
- IMUX N/A
- Revenue This Year
- ONL N/A
- IMUX N/A
- Revenue Next Year
- ONL N/A
- IMUX N/A
- P/E Ratio
- ONL N/A
- IMUX N/A
- Revenue Growth
- ONL N/A
- IMUX N/A
- 52 Week Low
- ONL $1.46
- IMUX $0.56
- 52 Week High
- ONL $4.39
- IMUX $2.11
- Technical
- Relative Strength Index (RSI)
- ONL 52.17
- IMUX 31.04
- Support Level
- ONL $1.63
- IMUX $0.56
- Resistance Level
- ONL $1.97
- IMUX $0.95
- Average True Range (ATR)
- ONL 0.11
- IMUX 0.07
- MACD
- ONL 0.01
- IMUX -0.03
- Stochastic Oscillator
- ONL 54.77
- IMUX 30.28
About ONL Orion Office REIT Inc.
Orion Properties Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased on a single-tenant net lease basis to creditworthy clients. The portfolio of the company includes traditional office buildings, governmental offices, medical offices, laboratories, and others. The Company operates in one business segment: direct ownership and operation of commercial real estate.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.